(Press-News.org) New research shows a drug commonly used to treat sickle cell anemia in adults reduces bouts of acute pain and a pneumonia-like illness, cuts hospitalization time and eases other symptoms of the disease in young patients. Results of the randomized, double-blind trial mark a dramatic advance in treatment of children with the inherited blood disorder.
"These results show that hydroxyurea has the potential to dramatically improve the quality of life for an entire generation of patients with sickle cell disease," said Winfred Wang, M.D., the study's principal investigator and a member of the St. Jude Children's Research Hospital Department of Hematology. He said the findings mean hydroxyurea should now be considered for treatment of all infant and toddlers with sickle cell anemia in hopes of preventing or delaying disease complications. The research will be published in the May 14 issue of the British medical journal The Lancet.
St. Jude researchers led the six-year Pediatric Hydroxyurea Phase III Clinical Trial, known as Baby HUG. The federally funded study involved 193 infants and toddlers enrolled at 13 participating U.S. medical centers and a coordinating center.
About 100,000 Americans have sickle cell anemia, a chronic disorder associated with a range of health problems, including an increased risk of strokes and premature death. Sickle cell anemia is the most common genetic disorder affecting Americans of African descent, but the disease also strikes persons of other racial and ethnic backgrounds.
Sickle cell anemia is caused by a gene mutation that leaves the red blood cells of sickle cell patients prone to assuming the stiff, crescent shape for which the disease is named. The misshapen cells can clog blood vessels, triggering pain crises, strokes and organ damage, including kidney failure. The drug works in part by increasing production of fetal hemoglobin, which counteracts the effects of the sickle hemoglobin. Fetal hemoglobin is the main hemoglobin produced by all newborns, but production normally decreases dramatically within a few months after birth.
While life expectancy for sickle cell anemia patients has improved in recent decades thanks in part to better supportive care, Wang said hydroxyurea is the first drug proven to reduce the incidence of a wide range of symptoms in extremely young sickle cell patients regardless of disease severity. The drug is inexpensive and easy to administer. The drug has been used for more than 15 years as a treatment for sickle cell disease with no evidence of serious side effects. Hydroxyurea began as a potential cancer treatment, but won U.S. Food and Drug Administration approval for use in adults with severe sickle cell disease. Baby HUG is the largest trial of hydroxyurea in much younger patients.
The Baby HUG trial was launched in 2003 after promising preliminary results regarding the drug's safety and effectiveness in extremely young children. The research included patients who were ages 9 to 18 months when they began the study. Participants were randomly assigned to receive either a standard dose of hydroxyurea or a placebo every day for two years. Neither the families nor the caregivers knew which children received hydroxyurea.
An analysis of 179 patients who completed at least 18 months of the study found children in the placebo group had nearly twice as many acute pain episodes, were three times more likely to suffer a pneumonia-like illness known as acute chest syndrome and five times more likely to develop painful swelling of the hands and feet called dactylitis. They were also slightly more likely to be hospitalized or need blood transfusions to ease sickle cell symptoms.
The most common side effect reported in this study was a mild-to-moderate drop in the white blood cells known as neutrophils, which occurred more often in children receiving hydroxyurea. Low neutrophil counts can be associated with an increased risk of infection, but there was no evidence of this in the Baby HUG trial.
Although results of kidney and spleen function tests were not significantly different between the Baby HUG treatment groups, Wang said other measures suggested that hydroxyurea might protect those organs as well as the brain and lungs from the chronic damage that leaves sickle cell anemia patients at increased risk for premature death. A follow-up study to Baby HUG is underway, focusing on possible long-term benefits from continued treatment with higher doses of hydroxyurea.
###
The study's other authors are Russell Ware, formerly of St. Jude; Lynn Wynn, of St. Jude; Scott Miller, SUNY Downstate Medical Center; Rathi Iyer, University of Mississippi Medical Center; James Casella, Johns Hopkins University School of Medicine; Caterina Minniti, Children's National Medical Center; Sohail Rana, Howard University College of Medicine; Courtney Thornburg, Duke University Medical Center; Zora Rogers, Southwestern Medical Center, Dallas; Ram Kalpatthi, Medical University of South Carolina; Julio Barredo and F. Daniel Armstrong, both of University of Miami; R. Clark Brown and Beatrice Files, both of Emory University School of Medicine; Sharada Sarnaik, Children's Hospital of Michigan; Thomas Howard, University of Alabama at Birmingham; Abdullah Kutlar, Medical College of Georgia; Jonathan Goldsmith and Myron Waclawiw, both of the National Heart, Lung, and Blood Institute (NHLBI); and Xiangke Huang and Bruce Thompson, both of the Clinical Trials and Surveys Corp.
NHLBI and the National Institute of Child Health and Human Development funded the research.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is internationally recognized for its pioneering research and treatment of children with cancer and other catastrophic diseases. Ranked the No. 1 pediatric cancer hospital by Parents magazine and the No. 1 children's cancer hospital by U.S. News & World Report, St. Jude is the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. St. Jude has treated children from all 50 states and from around the world, serving as a trusted resource for physicians and researchers. St. Jude has developed research protocols that helped push overall survival rates for childhood cancer from less than 20 percent when the hospital opened to almost 80 percent today. St. Jude is the national coordinating center for the Pediatric Brain Tumor Consortium and the Childhood Cancer Survivor Study. In addition to pediatric cancer research, St. Jude is also a leader in sickle cell disease research and is a globally prominent research center for influenza.
Founded in 1962 by the late entertainer Danny Thomas, St. Jude freely shares its discoveries with scientific and medical communities around the world, publishing more research articles than any other pediatric cancer research center in the United States. St. Jude treats more than 5,700 patients each year and is the only pediatric cancer research center where families never pay for treatment not covered by insurance. St. Jude is financially supported by thousands of individual donors, organizations and corporations without which the hospital's work would not be possible. For more information, go to www.stjude.org.
Sickle cell anemia drug safe and effective for infants and toddlers, adds treatment option
The multicenter Baby HUG trial led by St. Jude Children's Research Hospital investigators shows hydroxyurea reduces common symptoms of sickle cell anemia in children, raising hopes the drug will improve patient quality of life
2011-05-13
ELSE PRESS RELEASES FROM THIS DATE:
Activated graphene makes superior supercapacitors for energy storage
2011-05-13
UPTON, NY - Scientists at the U.S. Department of Energy's Brookhaven National Laboratory have helped to uncover the nanoscale structure of a novel form of carbon, contributing to an explanation of why this new material acts like a super-absorbent sponge when it comes to soaking up electric charge. The material, which was recently created at The University of Texas - Austin, can be incorporated into "supercapacitor" energy-storage devices with remarkably high storage capacity while retaining other attractive attributes such as superfast energy release, quick recharge time, ...
Younger patients, those with lower health literacy less likely
2011-05-13
Younger patients (under age 65) and those with lower health literacy were less likely to stick with telemonitoring technology for tracking their heart failure condition, compared to older patients and those with high health literacy skills, according to new research.
Telemonitoring systems use information technology to monitor patients remotely. They are rapidly emerging as a strategy to improve care for patients with heart failure, however, results are mixed. This study finds that patient characteristics are important in determining who will use new technologies and ...
Gap Adventures Offers Discount on Early Season Sailings to Antarctica
2011-05-13
To celebrate the launch of the upcoming Antarctic sailing season, Gap Adventures, the world's adventure travel leader, announces an early bird sale. Travellers who book on the first two sailings of the Antarctica Classic in-Depth tour, departing November 7 and 18, will receive a $1000 discount.
"We're excited to introduce the new Antarctic cruising season," says Will Bennett, Gap Adventures' director of operations aboard the M/S Expedition. "A visit to Earth's southernmost continent is truly a once in a lifetime experience, filled with many opportunities ...
Patients with language barriers take almost twice as long to get to the hospital
2011-05-13
Researchers analyzed English comprehension among 210 patients at four New York City hospitals who suffered heart attacks with a heart artery completely blocked. Doctors often refer to this type of heart attack as a STEMI, for ST-elevation myocardial infarction.
In follow-up telephone interviews, 34 of the patients (16.2 percent) spoke no English (65 percent spoke Spanish; 6 percent Russian; 6 percent Chinese; 23 percent spoke another language).
The patients who reported they understood no English took almost twice as long to get to the hospital compared to those who ...
Smarter treatment for killer infections
2011-05-13
Sepsis is a major killer in hospital intensive care units. Researchers at Case Western Reserve University School of Medicine have found that manipulating a genetic factor that can launch or throttle the body's defenses can improve survival rates during bacterial infection.
"Currently, our therapies for sepsis are very limited," said Mukesh K. Jain, MD, Ellery Sedgwick Jr. Chair, director of the Case Cardiovascular Research Institute, and professor of medicine at Case Western Reserve University School of Medicine and chief research officer of the Harrington-McLaughlin Heart ...
NYC Transcription Keeps Up with Transcription Technology and Can Transcribe Financial Transcriptions From Every Type of Audio Recording Device
2011-05-13
For over 18 years NYC Transcription has been providing reliable financial transcription service, corporate transcription service, and more. They are one of New York's leading medical transcription companies.
NYC Transcription offers affordable prices, charging by the audio minute; and the company guarantees 99% accuracy.
Recordings can be analog or digital, and NYC Transcription provides tips for improving the quality of analog recordings.
Analog tape transcription refers to transcription from cassette tapes or microcassettes, which are analog sources. NYC Transcription ...
UT Southwestern researchers find protein that might be key to cutting cancer cells' blood supply
2011-05-13
DALLAS – May 12, 2011 – UT Southwestern Medical Center researchers have discovered a protein that guides blood vessel development and eventually might lead to a treatment to keep cancer cells from spreading.
The researchers showed in mice that the Ras interacting protein 1 (Rasip1) is so specific and central to so many cellular processes that without it new blood vessels simply cannot form, said Dr. Ondine Cleaver, assistant professor of molecular biology at UT Southwestern and senior author of the study in the April issue of Developmental Cell.
"What we've found is ...
Sprint Fidelis leads can be safely extracted in high-volume facilities
2011-05-13
Extraction of the Sprint Fidelis lead (Medtronic) can be safely performed in an experienced large volume center, according to research presented at the 2011 Heart Rhythm Society (HRS) conference in San Francisco last week.
The Sprint Fidelis lead has been associated with increased failure rate which resulted in the lead being removed from the market in 2007. However, even if the lead does not fail, physicians are tasked with the decision as to whether or not to prophylactically remove the Sprint Fidelis leads, explained the study's lead author Raed H. Abdelhadi, MD, ...
MerchantServicesProfessionals.com Launches New Online Platform with $50 Satisfaction Assurance
2011-05-13
Merchant Services Professionals ("MSP") has taken superior merchant services to a much higher level. Along with exploding ecommerce and business globalization, MSP has rolled with the punches, risen to the occasion -- and met the challenges. The innovative, conscientious firm has launched a new website to better serve business customers' needs. MerchantServicesProfessionals.com is the virtual spot for "one-stop" servicing of virtually all business marketing and payment processing needs.
Since its 2009 inception, this New York-headquartered payment ...
Increase in Internet access parallels growth in prescription drug abuse
2011-05-13
Increasing access to rogue online pharmacies – those which dispense medications without a doctor's prescription – may be an important factor behind the rapid increase in the abuse of prescription drugs. In a report that was released today online by the journal Health Affairs and will also appear in its June edition, investigators from Massachusetts General Hospital (MGH) and the University of Southern California (USC) find that states with the greatest expansion in high-speed Internet access from 2000 to 2007 also had the largest increase in admissions for treatment of ...
LAST 30 PRESS RELEASES:
Call for papers: 14th Asia-Pacific Conference on Transportation and the Environment (APTE 2025)
A novel disturbance rejection optimal guidance method for enhancing precision landing performance of reusable rockets
New scan method unveils lung function secrets
Searching for hidden medieval stories from the island of the Sagas
Breakthrough study reveals bumetanide treatment restores early social communication in fragile X syndrome mouse model
Neuroscience leader reveals oxytocin's crucial role beyond the 'love hormone' label
Twelve questions to ask your doctor for better brain health in the new year
Microelectronics Science Research Centers to lead charge on next-generation designs and prototypes
Study identifies genetic cause for yellow nail syndrome
New drug to prevent migraine may start working right away
Good news for people with MS: COVID-19 infection not tied to worsening symptoms
Department of Energy announces $179 million for Microelectronics Science Research Centers
Human-related activities continue to threaten global climate and productivity
Public shows greater acceptance of RSV vaccine as vaccine hesitancy appears to have plateaued
Unraveling the power and influence of language
Gene editing tool reduces Alzheimer’s plaque precursor in mice
TNF inhibitors prevent complications in kids with Crohn's disease, recommended as first-line therapies
Twisted Edison: Bright, elliptically polarized incandescent light
Structural cell protein also directly regulates gene transcription
Breaking boundaries: Researchers isolate quantum coherence in classical light systems
Brain map clarifies neuronal connectivity behind motor function
Researchers find compromised indoor air in homes following Marshall Fire
Months after Colorado's Marshall Fire, residents of surviving homes reported health symptoms, poor air quality
Identification of chemical constituents and blood-absorbed components of Shenqi Fuzheng extract based on UPLC-triple-TOF/MS technology
'Glass fences' hinder Japanese female faculty in international research, study finds
Vector winds forecast by numerical weather prediction models still in need of optimization
New research identifies key cellular mechanism driving Alzheimer’s disease
Trends in buprenorphine dispensing among adolescents and young adults in the US
Emergency department physicians vary widely in their likelihood of hospitalizing a patient, even within the same facility
Firearm and motor vehicle pediatric deaths— intersections of age, sex, race, and ethnicity
[Press-News.org] Sickle cell anemia drug safe and effective for infants and toddlers, adds treatment optionThe multicenter Baby HUG trial led by St. Jude Children's Research Hospital investigators shows hydroxyurea reduces common symptoms of sickle cell anemia in children, raising hopes the drug will improve patient quality of life